SABRE: A New Era for Osteoporosis Trials
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
SABRE: A New Era for Osteoporosis Trials
-
Narrated by:
-
By:
About this listen
The lads sit down with Mary Bouxsein to explore SABRE — the landmark project aiming to make BMD a validated regulatory endpoint in osteoporosis trials. Mary walks us through how her team brought together data from more than 160,000 patients, why this could transform the speed and ethics of future drug development, and what it means for equity and patient care. A big conversation with one of the true leaders in the field — and a glimpse into a future where better treatments reach people faster.
Mary Bouxsein is the Maurice E. Mueller Professor of Orthopedic Surgery at Harvard Med School and Co-lead of the Study to Advance BMD as a Regulatory Endpoint (SABRE).
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.